Cargando…

Molecular Logic as a Means to Assess Therapeutic Antidotes

An emerging direction in the area of molecular logic and computation is developing molecular-scale devices that can operate in complex biological environments, such as within living cells, which are beyond the reach of conventional electronic devices. Herein we demonstrate, at the proof-of-principle...

Descripción completa

Detalles Bibliográficos
Autores principales: Unger-Angel, Linor, Motiei, Leila, Margulies, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499185/
https://www.ncbi.nlm.nih.gov/pubmed/31106191
http://dx.doi.org/10.3389/fchem.2019.00243
_version_ 1783415757098450944
author Unger-Angel, Linor
Motiei, Leila
Margulies, David
author_facet Unger-Angel, Linor
Motiei, Leila
Margulies, David
author_sort Unger-Angel, Linor
collection PubMed
description An emerging direction in the area of molecular logic and computation is developing molecular-scale devices that can operate in complex biological environments, such as within living cells, which are beyond the reach of conventional electronic devices. Herein we demonstrate, at the proof-of-principle level, how concepts applied in the field of molecular logic gates can be used to convert a simple fluorescent switch (YES gate), which lights up in the presence of glutathione s-transferase (GST), into a medicinally relevant INHIBIT gate that responds to both GST and beta-cyclodextrin (β-CD) as input signals. We show that the optical responses generated by this device indicate the ability to use it as an enzyme inhibitor, and more importantly, the ability to use β-CD as an “antidote” that prevents GST inhibition. The relevance of this system to biomedical applications is demonstrated by using the INHIBIT gate and β-CD to regulate the growth of breast cancer cells, highlighting the possibility of applying supramolecular inputs, commonly used to control the fluorescence of molecular logic gates, as antidotes that reverse the toxic effect of chemotherapy agents. We also show that the effect of β-CD can be prevented by introducing 1-adamantanecarboxylic acid (Ad-COOH) as an additional input signal, indicating the potential of obtaining precise, temporal control over enzyme activity and anticancer drug function.
format Online
Article
Text
id pubmed-6499185
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64991852019-05-17 Molecular Logic as a Means to Assess Therapeutic Antidotes Unger-Angel, Linor Motiei, Leila Margulies, David Front Chem Chemistry An emerging direction in the area of molecular logic and computation is developing molecular-scale devices that can operate in complex biological environments, such as within living cells, which are beyond the reach of conventional electronic devices. Herein we demonstrate, at the proof-of-principle level, how concepts applied in the field of molecular logic gates can be used to convert a simple fluorescent switch (YES gate), which lights up in the presence of glutathione s-transferase (GST), into a medicinally relevant INHIBIT gate that responds to both GST and beta-cyclodextrin (β-CD) as input signals. We show that the optical responses generated by this device indicate the ability to use it as an enzyme inhibitor, and more importantly, the ability to use β-CD as an “antidote” that prevents GST inhibition. The relevance of this system to biomedical applications is demonstrated by using the INHIBIT gate and β-CD to regulate the growth of breast cancer cells, highlighting the possibility of applying supramolecular inputs, commonly used to control the fluorescence of molecular logic gates, as antidotes that reverse the toxic effect of chemotherapy agents. We also show that the effect of β-CD can be prevented by introducing 1-adamantanecarboxylic acid (Ad-COOH) as an additional input signal, indicating the potential of obtaining precise, temporal control over enzyme activity and anticancer drug function. Frontiers Media S.A. 2019-04-16 /pmc/articles/PMC6499185/ /pubmed/31106191 http://dx.doi.org/10.3389/fchem.2019.00243 Text en Copyright © 2019 Unger-Angel, Motiei and Margulies. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Unger-Angel, Linor
Motiei, Leila
Margulies, David
Molecular Logic as a Means to Assess Therapeutic Antidotes
title Molecular Logic as a Means to Assess Therapeutic Antidotes
title_full Molecular Logic as a Means to Assess Therapeutic Antidotes
title_fullStr Molecular Logic as a Means to Assess Therapeutic Antidotes
title_full_unstemmed Molecular Logic as a Means to Assess Therapeutic Antidotes
title_short Molecular Logic as a Means to Assess Therapeutic Antidotes
title_sort molecular logic as a means to assess therapeutic antidotes
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499185/
https://www.ncbi.nlm.nih.gov/pubmed/31106191
http://dx.doi.org/10.3389/fchem.2019.00243
work_keys_str_mv AT ungerangellinor molecularlogicasameanstoassesstherapeuticantidotes
AT motieileila molecularlogicasameanstoassesstherapeuticantidotes
AT marguliesdavid molecularlogicasameanstoassesstherapeuticantidotes